Maxim raised the firm’s price target on Rezolute (RZLT) to $20 from $15 and keeps a Buy rating on the shares. The firm notes the shifting regulatory environment at FDA which, while inducing challenges for some drug categories, seems to have a more favorable view for rare disease, the analyst tells investors in a research note. Rezolute shares have also been rallying since late May stemming from multiple factors, initially with the completion of enrollment for the Phase 3 study of ersodetug in congenital hyperinsulinism announced on May 28, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute price target raised to $20 from $15 at Maxim
- Rezolute’s Promising Progress and Financial Strength Justify Buy Rating
- Rezolute’s Promising Outlook: Buy Rating Affirmed Amid Strategic Advancements and Strong Clinical Progress
- Rezolute, Inc. Reports Fiscal 2025 Financial Results
- Rezolute reports Q4 EPS (26c), consensus (23c)